<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Obes</journal-id><journal-id journal-id-type="iso-abbrev">BMC Obes</journal-id><journal-title-group><journal-title>BMC obesity</journal-title></journal-title-group><issn pub-type="epub">2052-9538</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26217542</article-id><article-id pub-id-type="pmc">4511449</article-id><article-id pub-id-type="publisher-id">56</article-id><article-id pub-id-type="doi">10.1186/s40608-015-0056-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Dose and time responses of vitamin D biomarkers to monthly vitamin D<sub>3</sub> supplementation in overweight/obese African Americans with suboptimal vitamin d status: a placebo controlled randomized clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bhagatwala</surname><given-names>Jigar</given-names></name><address><email>jbhagatwala@gru.edu</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Haidong</given-names></name><address><email>hzhu@gru.edu</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Parikh</surname><given-names>Samip J.</given-names></name><address><email>sparikh@gru.edu</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Guo</surname><given-names>De-Huang</given-names></name><address><email>dguo@gru.edu</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Kotak</surname><given-names>Ishita</given-names></name><address><email>iskotak@gru.edu</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Ying</given-names></name><address><email>yihuang@gru.edu</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Havens</surname><given-names>Robyn</given-names></name><address><email>rhavens@gru.edu</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Pham</surname><given-names>Michael</given-names></name><address><email>mpham@gru.edu</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Afari</surname><given-names>Eric</given-names></name><address><email>eafari@gru.edu</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Susan</given-names></name><address><email>sukim@gru.edu1</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Cutler</surname><given-names>Christopher</given-names></name><address><email>chcutler@gru.edu</email></address><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Pollock</surname><given-names>Norman K.</given-names></name><address><email>npollock@gru.edu</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Dong</surname><given-names>Yutong</given-names></name><address><email>yudong@gru.edu</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Raed</surname><given-names>Anas</given-names></name><address><email>araed@gru.edu</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Dong</surname><given-names>Yanbin</given-names></name><address><phone>(706) 721 5014</phone><email>ydong@gru.edu</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><label/>Georgia Prevention Institute, Medical College of Georgia, Georgia Regents University, Building HS-1640, Augusta, 30912-3715 GA USA </aff><aff id="Aff2"><label/>Department of Internal Medicine, Medical College of Georgia, Georgia Regents University, Augusta, GA USA </aff><aff id="Aff3"><label/>College of Nursing, Georgia Regents University, Augusta, GA USA </aff><aff id="Aff4"><label/>College of Dental Medicine, Georgia Regents University, Augusta, GA USA </aff></contrib-group><pub-date pub-type="epub"><day>4</day><month>7</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>4</day><month>7</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>2</volume><elocation-id>27</elocation-id><history><date date-type="received"><day>25</day><month>4</month><year>2015</year></date><date date-type="accepted"><day>29</day><month>5</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; Bhagatwala et al. 2015</copyright-statement><license license-type="open-access"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>A critical need exists to better understand the physiological sequel of vitamin D supplementation in obese individuals and African Americans. The aim was to comprehensively evaluate dose- and time-responses of a panel of vitamin D biomarkers to vitamin D supplements in this population.</p></sec><sec><title>Methods</title><p>We conducted a 16-week randomized, double-blinded, and placebo-controlled clinical trial. Seventy overweight/obese African Americans (age 13&#x02013;45 years, 84&#x000a0;% females) with 25-hydroxyvitamin D [25(OH)D] concentrations &#x02264;20&#x000a0;ng/mL were randomly assigned to receive a supervised monthly oral vitamin D<sub>3</sub> of 18,000&#x000a0;IU (~600&#x000a0;IU/day, <italic>n</italic>&#x02009;=&#x02009;17), 60,000&#x000a0;IU (~2000&#x000a0;IU/day, <italic>n</italic>&#x02009;=&#x02009;18), 120,000&#x000a0;IU (~4000&#x000a0;IU/day, <italic>n</italic>&#x02009;=&#x02009;18), or placebo (<italic>n</italic>&#x02009;=&#x02009;17).</p></sec><sec><title>Results</title><p>There were significant dose- and time-responses of circulating 25(OH)D, 1,25-dihydroxyvitamin D [1,25(OH)<sub>2</sub>D], and intact parathyroid hormone (iPTH), but not fibroblast growth factor-23 (FGF-23), phosphorus and urine calcium to the vitamin D supplements. The mean 25(OH)D concentrations in the 2000&#x000a0;IU and 4000&#x000a0;IU groups reached &#x02265;30&#x000a0;ng/mL as early as 8-weeks and remained at&#x000a0;similar level at 16-weeks. The increase of 25(OH)D was significantly higher in the 4000&#x000a0;IU group than all the other groups at 8-weeks. The increase of 1,25(OH)<sub>2</sub>D was significantly higher in the 2000&#x000a0;IU and 4000&#x000a0;IU groups than the placebo at 8-weeks. Only the 4000&#x000a0;IU compared to the placebo significantly reduced iPTH at 8- and 16-weeks.</p></sec><sec><title>Conclusions</title><p>Our RCT, for the first time, comprehensively evaluated time- and dose- responses of vitamin D supplementation in overweight/obese African Americans with suboptimal vitamin D status. Circulating 25(OH)D, 1,25(OH)2D, and iPTH, but not FGF-23, phosphorus and urine calcium, respond to vitamin D supplementation in a time- and dose&#x02013;response manner. By monthly dosing, 2000&#x000a0;IU appears to be sufficient in achieving a 25(OH)D level of 30&#x000a0;ng/mL in this population. However, importantly, 4000&#x000a0;IU, rather than 2000&#x000a0;IU, seems to suppress iPTH. If replicated, these data might be informative in optimizing vitamin D status and providing individualized dosing recommendation in overweight/obese African Americans.</p></sec><sec><title>Trial registration</title><p>ClinicalTrials.gov number: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01583621?term=d-sunny&#x00026;rank=1">NCT01583621</ext-link>, Registered on April 3, 2012.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Monthly vitamin D</kwd><kwd>Overweight/obese</kwd><kwd>African Americans</kwd><kwd>Dose&#x02013;response vitamin D</kwd><kwd>4000&#x000a0;IU vitamin D</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>African Americans as compared to their Caucasian peers have disproportionately high prevalence of suboptimal vitamin D status [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. Obesity, a risk factor for poor vitamin D status, also negatively impacts 25(OH)D responses to vitamin D supplementation [<xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>]. The most recent Institute of Medicine (IOM) Report identified an urgent need to conduct randomized clinical trials (RCTs) of vitamin D supplementation to clarify dose&#x02013;response to intake, with a special emphasis on the individuals with excess adiposity and dark skin pigmentations [<xref ref-type="bibr" rid="CR6">6</xref>]. Given the lack of conclusive evidence, the IOM bases its Recommended Dietary Allowance (RDA) for vitamin D on bone health, which is 600&#x02013;800&#x000a0;IU/day corresponding to a 25(OH)D serum level of ~20&#x000a0;ng/mL [<xref ref-type="bibr" rid="CR6">6</xref>]. The target 25(OH)D level is ~30&#x000a0;ng/mL recommended by many other experts for large swaths of the population, although it is controversial [<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>].</p><p>In an earlier placebo-controlled RCT, 208 healthy postmenopausal African American females residing in New York (~40.8&#x000b0;N latitude) were given a daily dose of 800&#x000a0;IU vitamin D plus calcium for two years [<xref ref-type="bibr" rid="CR11">11</xref>]. The mean 25(OH)D levels remained &#x0003c;30&#x000a0;ng/mL at the end of the second year, but reached up to 35&#x000a0;ng/mL within three months after the dose was increased to 2000&#x000a0;IU. However, approximately 40&#x000a0;% of participants still had 25(OH)D levels between 20&#x02013;30&#x000a0;ng/mL. The authors suggested a dose between 2800-4000&#x000a0;IU/day to optimize vitamin D levels in African Americans, according to the vitamin D algorithm. Gallagher and colleagues [<xref ref-type="bibr" rid="CR12">12</xref>] supplemented 110 postmenopausal African American females with suboptimal vitamin D status living in Nebraska (~41&#x000b0;N latitude) and Indiana (~40&#x000b0;N latitude) with daily doses between 400&#x02013;4800&#x000a0;IU vitamin D plus calcium for 12&#x000a0;months. The authors determined that a daily dose of 1600&#x000a0;IU was required to achieve the level of 25(OH)D &#x02265;30&#x000a0;ng/mL. In another study of younger (25&#x02013;45 years) African American (<italic>n</italic>&#x02009;=&#x02009;39) and Caucasian (<italic>n</italic>&#x02009;=&#x02009;90) females living in Nebraska, 400&#x02013;2400&#x000a0;IU/day vitamin D plus calcium supplements resulted in a dose and time-responsive increase in serum 25(OH)D concentrations. The authors estimated a daily dose between 800&#x02013;1600&#x000a0;IU in young African American females, to achieve a level of serum 25(OH)D at 20&#x000a0;ng/mL [<xref ref-type="bibr" rid="CR12">12</xref>]. More recently, Ng et al., [<xref ref-type="bibr" rid="CR13">13</xref>] supplemented 30&#x02013;80 years-old 328 African Americans living in Boston (42&#x000b0;N latitude) with daily 1000, 2000, or 4000&#x000a0;IU of vitamin D plus calcium for 3&#x000a0;months. It was estimated that a dose of 1640&#x000a0;IU and 4000&#x000a0;IU vitamin D is desired to achieve the 25(OH)D concentrations of &#x02265;20&#x000a0;ng/mL and &#x02265;33&#x000a0;ng/mL, respectively. However, dose-responsive RCTs with exclusive vitamin D supplementation are lacking in young African Americans, particularly in overweight/obese individuals.</p><p>Circulating 25(OH)D is converted by the enzyme 1-&#x003b1; hydroxylase to 1,25-dihydroxyvitamin D [1,25(OH)<sub>2</sub>D], the active form of vitamin D, which is responsible for the biological actions on calcium and phosphate homeostasis. 1,25(OH)<sub>2</sub>D has suppressive effects on parathyroid hormone (PTH) release and the level at which 25(OH)D begins to suppress PTH has been utilized to define vitamin D sufficiency [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Fibroblast growth factor-23 (FGF-23), a protein secreted from bone, plays a major role in the regulation of conversion of 25(OH)D to 1,25(OH)<sub>2</sub>D by suppressing 1-&#x003b1; hydroxylase. FGF-23 also enhances the expression of 24-hydroxylase, an enzyme that converts 1,25(OH)<sub>2</sub>D into a metabolite with much less biologic activity [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. The major regulators of FGF-23 release are 1,25(OH)<sub>2</sub>D, phosphate and PTH [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. However, there is paucity of dose-responsive RCTs evaluating changes of these vitamin D biomarkers to vitamin D supplementation, particularly in African Americans.</p><p>Therefore, the main objective of the current RCT was to study dose- and time-responses to vitamin D<sub>3</sub> supplements of 600&#x000a0;IU/day (current recommended dietary allowance, RDA), 2000&#x000a0;IU/day (previously the tolerable upper intake level [UL]) [<xref ref-type="bibr" rid="CR20">20</xref>] and 4000&#x000a0;IU/day (the new UL) on circulating 25(OH)D, 1,25(OH)<sub>2</sub>D, PTH, FGF-23, phosphorus, and urinary calcium in apparently healthy young overweight/obese African Americans with suboptimal vitamin D status residing in Southeastern United States. The present RCT undertook a monthly dosage scheme. Monthly dosing that is expected to improve compliance compared to daily dosage is commonly practiced for vitamin D supplementation [<xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>]. However, dose- and time- responses by monthly dosing are not well understood.</p></sec><sec id="Sec2"><title>Subject and methods</title><sec id="Sec3"><title>Participants</title><p>In this randomized, double-blinded, placebo-controlled clinical trial (clinicaltrials.gov registration#: NCT01583621), participants were recruited from community by advertisements and by word of mouth. Inclusion criteria were self-reported African American race, age between 13&#x02013;45 years, overweight/obese, no pregnancy, no lactation, no known acute or chronic illnesses, no use of any prescription medications, birth control pills, herbal, multi-vitamin or mineral supplementations, and suboptimal vitamin D status (serum 25(OH)D concentrations of &#x02264;20&#x000a0;ng/mL) [<xref ref-type="bibr" rid="CR6">6</xref>] at screening visit. Overweight/obesity was defined by body mass index (BMI) &#x02265;25&#x000a0;kg/m<sup>2</sup> for adults and &#x02265;85<sup>th</sup> percentile for age and sex for adolescents according to the Center of Disease Control and Prevention (CDC) criteria. The study was approved by the institutional review board (IRB) at the Georgia Regents University (GRU). Adolescents and their guardians provided informed written assent and consent, respectively; and the adults provided informed consent. A total of 129 overweight/obese African Americans living in Augusta, GA and surrounding areas were screened and 70 eligible subjects were enrolled and followed-up in the between December, 2011 and November, 2012. The trial registration on clinicaltrials.gov was delayed due to an oversight, and the authors confirm that all ongoing and related trials for this intervention are registered.</p></sec><sec id="Sec4"><title>Randomization and vitamin D<sub>3</sub> dosing</title><p>As presented in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>, participants were randomly assigned to either of the following vitamin D supplement groups: 18,000&#x000a0;IU (equivalent to 600&#x000a0;IU/day), 60,000&#x000a0;IU (equivalent to 2000&#x000a0;IU/day), 120,000&#x000a0;IU (equivalent to 4000&#x000a0;IU/day) or a placebo for 16&#x000a0;weeks by supervised monthly dosing. The vitamin D and placebo capsules were provided by the Bio-Tech Pharmacal, Fayetteville, AR, and the GRU clinical research pharmacy generated the randomization codes and dispensed the study capsules. The GRU clinical pharmacy maintained the randomization codes until the end of the study and did not have any direct role in the data collection.<fig id="Fig1"><label>Fig. 1</label><caption><p>Randomization scheme and group details (CONSORT 2010 flow chart). 25(OH)D: 25-hydroxyvitamin D</p></caption><graphic xlink:href="40608_2015_56_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec5"><title>Laboratory tests</title><p>Fasting blood samples and spot urine samples were obtained at baseline, 8- and 16-weeks, which were frozen and stored at &#x02212;80&#x000a0;&#x000b0;C until assayed. Serum 25(OH)D concentrations were measured using enzyme immunoassay (Immunodiagnostic Systems, Fountain Hills, AZ). The intra- and inter-assay coefficients of variation (CV) were 5.6 and 6.6&#x000a0;%, respectively. Our laboratory is certified by the vitamin D external quality assessment scheme (DEQAS), an international program monitoring accuracy of 25(OH)D measurements. Plasma 1,25(OH)<sub>2</sub>D levels were measured using radioimmunoassay [<xref ref-type="bibr" rid="CR24">24</xref>]. The intra- and inter-assay CVs were 9.8&#x000a0;% and 12.6&#x000a0;%, respectively. Plasma bioactive intact parathyroid hormone (iPTH) concentrations were measured using an enzyme-linked immunosorbent assay (ELISA, Immutopics, San Clemente, CA). Plasma intact FGF-23 concentrations were measured using ELISA (Immunotopics, Inc., San Clemente, CA). The intra- and inter-assay CVs were and 6.7&#x000a0;% and 9.8&#x000a0;%, respectively. Plasma phosphorus was determined using colorimetric assays kits (Point Scientific, Inc., Canton, MI). The intra- and inter-assay CVs were 6.4&#x000a0;% and 8.1&#x000a0;%, respectively. Spot urine calcium levels were measured by BioVision&#x02019;s Colorimetric Calcium Assay Kits. The urine calcium normalized by urine creatinine (Ca/Cr) was used to monitor toxicity.</p></sec><sec id="Sec6"><title>Sample size estimation</title><p>Power calculations were computed based on primary outcomes 25(OH)D, 1,25(OH)<sub>2</sub>D, iPTH, and FGF-23. The computations are based upon the linear contrast approach for the main effect of treatment, rather than the traditional omnibus F-test followed by post hoc pairwise comparisons, because a pre-specified contrast conditioned on the ordering of responses is more powerful to detect the expected pattern, without sacrificing control of type I error. Required are assumptions concerning the difference in mean 16-week changes in the response (i.e., differences in the mean gain scores) across treatment arms, and the variance of the gain score, from which effect size is computed. Using previous data, including ours, [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>] we pooled estimates in standard deviation (SD) of change for 25(OH)D (SD&#x02009;=&#x02009;5.1&#x000a0;ng/mL), 1,25(OH)<sub>2</sub>D (SD&#x02009;=&#x02009;4.0&#x000a0;pg/mL), iPTH (SD&#x02009;=&#x02009;3.5&#x000a0;pg/mL) and FGF-23 (SD&#x02009;=&#x02009;1.2&#x000a0;pg/mL), and we estimated effect sizes (i.e., Cohen&#x02019;s <italic>d</italic>) for these outcomes [25(OH)D, <italic>d</italic>&#x02009;=&#x02009;3.0; 1,25(OH)<sub>2</sub>D, <italic>d</italic>&#x02009;=&#x02009;1.2; iPTH, <italic>d</italic>&#x02009;=&#x02009;0.65; and FGF-23, <italic>d</italic>&#x02009;=&#x02009;0.53] based on the assumption that the 600&#x000a0;IU and 2000&#x000a0;IU groups would have one-quarter and one-half the mean change, respectively, of that occurring in the 4000&#x000a0;IU group, relative to the mean change in the control group. We determined that 10&#x02013;16 subjects/group would provide 81-96&#x000a0;% power (&#x003b1;&#x02009;=&#x02009;0.05) to detect a difference in mean change of the outcome variable between groups. With a given sample size of 16 subject/group (&#x003b1;-level set at 0.05), the proposed study will have power of 0.81. Assuming a 10&#x000a0;% sample size loss due to attrition or insufficient quality of measurements, a starting sample size of 18 subjects per group will preserve power of the study design.</p></sec><sec id="Sec7"><title>Statistical analyses</title><p>All statistical analyses were performed using SPSS software (IBM Corp. Released 2011. IBM SPSS Statistics for Windows, version 21.0. Armonk, NY) and statistical significance was set at P&#x02009;&#x0003c;&#x02009;0.05. Analysis of variance was used to compare group differences at baseline for normally distributed variables or by Kruskal-Wallis test, otherwise. Differences in proportions were tested by chi-square test of goodness of fit.</p><p>Repeated-measures mixed-models were used with maximum likelihood estimation in an intention-to-treat analysis of each outcome measure using all available data. Base models for each outcome measure included the fixed effects of intervention group (placebo, 600&#x000a0;IU/day, 2000&#x000a0;IU/day, or 4000&#x000a0;IU/day) and measurement time (baseline, 8-weeks, or 16-weeks) and their interaction. The modeled covariance structure between measurement periods was unstructured, which used all available measurements on the same subject, including those from subjects who dropped out of the study. Because significant group differences in baseline characteristics were not detected, covariates were not considered in the primary analyses. However, secondary analyses were performed to consider potential effects of age, gender, season, and BMI. The linear contrasts across the four groups of the change over time tested the dose&#x02013;response effects of vitamin D supplementation, and the pairwise comparisons of changes in the outcome variables between groups were performed.</p></sec></sec><sec id="Sec8" sec-type="results"><title>Results</title><sec id="Sec9"><title>Baseline clinical characteristics</title><p>Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> displays the baseline characteristics of the participants. Of 129 screened, ~75&#x000a0;% (96 individuals) met the inclusion criteria. A total of 70 subjects were available at baseline. The baseline serum 25(OH)D in the entire sample was 14.77&#x02009;&#x000b1;&#x02009;0.6&#x000a0;ng/mL. Age, gender distribution, BMI, serum 25(OH)D, plasma iPTH, 1,25(OH)<sub>2</sub>D, FGF-23 and phosphorus did not differ among the groups at baseline. No side effects were observed during the study period. A total of 5 participants discontinued the study either due to loss of follow up (2 subjects), positive pregnancy test (2 subjects) or diagnosis of diabetes (1 subject).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline clinical characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th colspan="4">Study groups</th><th>
<italic>P</italic>-value</th></tr><tr><th/><th>Placebo (<italic>n</italic>&#x02009;=&#x02009;17)</th><th>600&#x000a0;IU/day (<italic>n</italic>&#x02009;=&#x02009;17)</th><th>2000&#x000a0;IU/day (<italic>n</italic>&#x02009;=&#x02009;18)</th><th>4000&#x000a0;IU/day (<italic>n</italic>&#x02009;=&#x02009;18)</th><th/></tr></thead><tbody><tr><td>Age (years)</td><td char="&#x000b1;" align="char">27.78&#x02009;&#x000b1;&#x02009;2.6</td><td char="&#x000b1;" align="char">26.19&#x02009;&#x000b1;&#x02009;2.5</td><td char="&#x000b1;" align="char">24.38&#x02009;&#x000b1;&#x02009;2.0</td><td char="&#x000b1;" align="char">25.51&#x02009;&#x000b1;&#x02009;2.2</td><td char="." align="char">0.77</td></tr><tr><td>Male/Female<sup>a</sup>
</td><td char="/" align="char">4/12</td><td char="/" align="char">2/13</td><td char="/" align="char">3/14</td><td char="/" align="char">2/15</td><td char="." align="char">0.76</td></tr><tr><td>Height (cm)</td><td char="&#x000b1;" align="char">164.28&#x02009;&#x000b1;&#x02009;2.1</td><td char="&#x000b1;" align="char">164.60&#x02009;&#x000b1;&#x02009;2.0</td><td char="&#x000b1;" align="char">163.84&#x02009;&#x000b1;&#x02009;2.4</td><td char="&#x000b1;" align="char">164.20&#x02009;&#x000b1;&#x02009;1.7</td><td char="." align="char">0.99</td></tr><tr><td>Weight (kg)</td><td char="&#x000b1;" align="char">98.42&#x02009;&#x000b1;&#x02009;6.7</td><td char="&#x000b1;" align="char">93.39&#x02009;&#x000b1;&#x02009;3.7</td><td char="&#x000b1;" align="char">99.16&#x02009;&#x000b1;&#x02009;5.0</td><td char="&#x000b1;" align="char">92.77&#x02009;&#x000b1;&#x02009;4.8</td><td char="." align="char">0.74</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td char="&#x000b1;" align="char">36.19&#x02009;&#x000b1;&#x02009;2.0</td><td char="&#x000b1;" align="char">34.56&#x02009;&#x000b1;&#x02009;1.4</td><td char="&#x000b1;" align="char">37.08&#x02009;&#x000b1;&#x02009;1.9</td><td char="&#x000b1;" align="char">34.42&#x02009;&#x000b1;&#x02009;1.7</td><td char="." align="char">0.66</td></tr><tr><td>Serum 25(OH)D (ng/mL)</td><td char="&#x000b1;" align="char">15.88&#x02009;&#x000b1;&#x02009;1.4</td><td char="&#x000b1;" align="char">14.00&#x02009;&#x000b1;&#x02009;0.8</td><td char="&#x000b1;" align="char">15.93&#x02009;&#x000b1;&#x02009;1.0</td><td char="&#x000b1;" align="char">13.25&#x02009;&#x000b1;&#x02009;1.0</td><td char="." align="char">0.21</td></tr><tr><td>Plasma iPTH (pg/mL)<sup>#</sup>
</td><td char="&#x000b1;" align="char">47.32&#x02009;&#x000b1;&#x02009;3.6</td><td char="&#x000b1;" align="char">59.60&#x02009;&#x000b1;&#x02009;7.8</td><td char="&#x000b1;" align="char">50.60&#x02009;&#x000b1;&#x02009;4.2</td><td char="&#x000b1;" align="char">62.00&#x02009;&#x000b1;&#x02009;8.8</td><td char="." align="char">0.32</td></tr><tr><td>Plasma 1,25(OH)<sub>2</sub>D (pg/mL)</td><td char="&#x000b1;" align="char">34.04&#x02009;&#x000b1;&#x02009;1.9</td><td char="&#x000b1;" align="char">37.40&#x02009;&#x000b1;&#x02009;1.8</td><td char="&#x000b1;" align="char">35.18&#x02009;&#x000b1;&#x02009;2.3</td><td char="&#x000b1;" align="char">32.70&#x02009;&#x000b1;&#x02009;1.1</td><td char="." align="char">0.46</td></tr><tr><td>Plasma FGF-23 (pg/mL)<sup>#</sup>
</td><td char="&#x000b1;" align="char">6.53&#x02009;&#x000b1;&#x02009;0.9</td><td char="&#x000b1;" align="char">6.92&#x02009;&#x000b1;&#x02009;0.8</td><td char="&#x000b1;" align="char">8.57&#x02009;&#x000b1;&#x02009;1.6</td><td char="&#x000b1;" align="char">6.57&#x02009;&#x000b1;&#x02009;0.9</td><td char="." align="char">0.81</td></tr><tr><td>Plasma Phosphorus (mg/dL)<sup>#</sup>
</td><td char="&#x000b1;" align="char">3.74&#x02009;&#x000b1;&#x02009;0.2</td><td char="&#x000b1;" align="char">4.01&#x02009;&#x000b1;&#x02009;0.3</td><td char="&#x000b1;" align="char">3.61&#x02009;&#x000b1;&#x02009;0.1</td><td char="&#x000b1;" align="char">3.80&#x02009;&#x000b1;&#x02009;0.1</td><td char="." align="char">0.71</td></tr><tr><td>Urine Ca/Cr ratio</td><td char="&#x000b1;" align="char">0.08&#x02009;&#x000b1;&#x02009;0.05</td><td char="&#x000b1;" align="char">0.05&#x02009;&#x000b1;&#x02009;0.03</td><td char="&#x000b1;" align="char">0.10&#x02009;&#x000b1;&#x02009;0.05</td><td char="&#x000b1;" align="char">0.08&#x02009;&#x000b1;&#x02009;0.05</td><td char="." align="char">0.09</td></tr></tbody></table><table-wrap-foot><p>Values are presented as mean&#x02009;&#x000b1;&#x02009;s.e.m</p><p>
<italic>BMI</italic> Body mass index, <italic>25(OH)D</italic> Serum 25-hydroxyvitamin D, <italic>Plasma 1,25(OH)</italic>
<sub><italic>2</italic></sub>
<italic>D</italic> 1,25-dihydroxyvitamin D, <italic>iPTH</italic> Intact parathyroid hormone, <italic>FGF-23</italic> Fibroblast Growth Factor-23, <italic>Ca/Cr</italic> Calcium/creatinine ratio</p><p>
<sup>a</sup>Group differences analyzed using chi-square test</p><p>
<sup>#</sup>Group differences analyzed using Kruskal-Wallis test</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec10"><title>25 (OH)D: dose and time responses at 8- and 16-weeks</title><p>There were overall group by time interactions (P&#x02009;&#x0003c;&#x02009;0.01), suggesting dose- and time-dependent increases in serum 25(OH)D concentrations to the monthly vitamin D supplements (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). In the 600&#x000a0;IU group, mean 25(OH)D concentrations remained ~20&#x000a0;ng/mL both at 8- (21.0&#x02009;&#x000b1;&#x02009;1.0&#x000a0;ng/mL) and 16-weeks (22.61&#x02009;&#x000b1;&#x02009;1.24&#x000a0;ng/mL). On the other hand, both 2000&#x000a0;IU and 4000&#x000a0;IU vitamin D groups raised mean 25(OH)D concentrations to the level of 30&#x000a0;ng/mL at 8-weeks (30.50&#x02009;&#x000b1;&#x02009;2.1 and 35.66&#x02009;&#x000b1;&#x02009;3.4&#x000a0;ng/mL, respectively), and maintained at a similar level (36.01&#x02009;&#x000b1;&#x02009;3.1 and 34.80&#x02009;&#x000b1;&#x02009;2.4&#x000a0;ng/mL, respectively) at 16-weeks.<fig id="Fig2"><label>Fig. 2</label><caption><p>Dose- and time-responses of 25(OH)D. Intention-to-treat mixed-model repeated-measures analysis of variance of the effect of group on serum 25-hydroxyvitamin D [25(OH)D], the <italic>P</italic>-value in each panel indicates the test of the dose&#x02013;response trend. Error bars indicate 95&#x000a0;% confidence intervals</p></caption><graphic xlink:href="40608_2015_56_Fig2_HTML" id="MO2"/></fig></p><p>In post-hoc group-wise comparison, the changes in 25(OH)D concentrations from baseline to 8-weeks in the 4000&#x000a0;IU group (22.41&#x02009;&#x000b1;&#x02009;1.8&#x000a0;ng/mL) were significantly greater compared to the 2000&#x000a0;IU (14.56&#x02009;&#x000b1;&#x02009;1.8&#x000a0;ng/mL, p&#x02009;&#x0003c;&#x02009;0.01), 600&#x000a0;IU (7.06&#x02009;&#x000b1;&#x02009;2.0&#x000a0;ng/mL, p&#x02009;&#x0003c;&#x02009;0.01) and placebo (0.12&#x02009;&#x000b1;&#x02009;1.9&#x000a0;ng/mL, p&#x02009;&#x0003c;&#x02009;0.01) groups. At 16-weeks, however, the changes in 25(OH)D concentrations in the 4000&#x000a0;IU group plateaued and were similar to the changes in the 2000&#x000a0;IU group (21.51&#x02009;&#x000b1;&#x02009;2.0 vs. 20.08&#x02009;&#x000b1;&#x02009;2.0&#x000a0;ng/mL, <italic>p</italic>&#x02009;=&#x02009;0.60). Within the 4000&#x000a0;IU group, 25(OH)D concentrations at 16-weeks did not differ from those at 8-weeks (34.77&#x02009;&#x000b1;&#x02009;2.5 vs. 35.66&#x02009;&#x000b1;&#x02009;3.4&#x000a0;ng/mL, <italic>p</italic>&#x02009;=&#x02009;0.60). However, within the 2000&#x000a0;IU group, 25(OH)D concentrations at 16-weeks were significantly higher than those at 8-weeks (36.01&#x02009;&#x000b1;&#x02009;3.1 vs. 30.50&#x02009;&#x000b1;&#x02009;2.1&#x000a0;ng/mL, <italic>p</italic>&#x02009;=&#x02009;0.02).</p></sec><sec id="Sec11"><title>1,25 (OH)<sub>2</sub>D: dose and time responses at 8- and 16-weeks</title><p>There were overall group by time interactions (<italic>P</italic>&#x02009;=&#x02009;0.046), suggesting dose- and time-dependent increases in plasma 1,25(OH)<sub>2</sub>D concentrations to the monthly vitamin D supplements (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). In post-hoc group-wise comparisons, the changes from baseline to 8-weeks, but not the changes from baseline to 16-weeks, were significantly higher both in the 4000&#x000a0;IU and 2000&#x000a0;IU groups versus the placebo group. However, only the 4000&#x000a0;IU group showed a greater increase than the 600&#x000a0;IU group (8.89&#x02009;&#x000b1;&#x02009;2.0&#x000a0;pg/mL vs. 2.95&#x02009;&#x000b1;&#x02009;2.1&#x000a0;pg/mL, <italic>p</italic>&#x02009;=&#x02009;0.04) at 8-weeks. The increases of 1,25(OH)<sub>2</sub>D concentrations at 16-weeks in the 4000&#x000a0;IU group versus the placebo or 600&#x000a0;IU group was marginally significant (<italic>p</italic>&#x02009;=&#x02009;0.07 and 0.08, respectively). Nevertheless, the increases of 1,25(OH)<sub>2</sub>D in the 600&#x000a0;IU group were not statistically significant either at 8- or 16-weeks.<fig id="Fig3"><label>Fig. 3</label><caption><p>Dose- and time-responses of 1,25(OH)<sub>2</sub>D. Intention-to-treat mixed-model repeated-measures analysis of variance of the effect of group on plasma 1,25-dihydroxyvitamin D [1,25(OH)<sub>2</sub>D], the <italic>P</italic>-value in each panel indicates the test of the dose&#x02013;response trend. Error bars indicate 95&#x000a0;% confidence intervals</p></caption><graphic xlink:href="40608_2015_56_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec12"><title>PTH: dose and time responses at 8- and 16-weeks</title><p>There were overall group by time interactions (<italic>p</italic>&#x02009;=&#x02009;0.042), suggesting dose- and time-dependent reductions in plasma iPTH concentrations to the monthly vitamin D supplements (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). A post-hoc group-wise comparison showed that iPTH concentrations reduced significantly from baseline only in the 4000&#x000a0;IU group, rather than the 600 or 2000&#x000a0;IU group, both at 8-weeks and 16-weeks (p&#x02009;&#x0003c;&#x02009;0.05), as compared to the placebo group. The changes did not differ among the other groups either at 8- or 16-weeks.<fig id="Fig4"><label>Fig. 4</label><caption><p>Dose- and time-responses of iPTH. Intention-to-treat mixed-model repeated-measures analysis of variance of the effect of group on plasma intact parathyroid hormone (iPTH), the <italic>P</italic>-value in each panel indicates the test of the dose&#x02013;response trend. Error bars indicate 95&#x000a0;% confidence intervals</p></caption><graphic xlink:href="40608_2015_56_Fig4_HTML" id="MO4"/></fig></p></sec><sec id="Sec13"><title>Plasma FGF-23, phosphorus and urine Ca/Cr ratio: dose and time responses at 8- and 16-weeks</title><p>There were not significant overall group by time interactions in FGF-23, phosphorus, and urine Ca/Cr ratio either at 8- or 16-weeks (all p&#x02009;&#x0003e;&#x02009;0.05).</p></sec></sec><sec id="Sec14" sec-type="discussion"><title>Discussion</title><p>To our knowledge, this is the first dose&#x02013;response vitamin D supplementation RCT comprehensively evaluating vitamin D responses in overweight/obese African Americans with suboptimal vitamin D status. Our major findings include: 1) vitamin D<sub>3</sub> supplements by monthly dosing increased circulating 25(OH)D and 1,25(OH)D; and suppressed iPTH in a time- and dose-dependent manner; 2) both 2000&#x000a0;IU/day and 4000&#x000a0;IU/day, rather than 600&#x000a0;IU/day, achieved the 25(OH)D level of 30&#x000a0;ng/mL. Although 4000&#x000a0;IU/day was not superior to 2000&#x000a0;IU/day in increasing 25(OH)D concentrations, 4000&#x000a0;IU/day increased 25(OH)D concentrations more rapidly than 2000&#x000a0;IU/day by monthly dosing; 3) Perhaps more importantly, only 4000&#x000a0;IU/day suppressed iPTH; and 4) plasma FGF-23, phosphorus and urine calcium did not change in time- or dose- dependent manner.</p><sec id="Sec15"><title>25(OH)D</title><p>Only few RCTs have studied dose-responsiveness to vitamin D supplementation in African Americans. We report for the first time that monthly vitamin D<sub>3</sub> raises serum 25(OH)D concentrations in a dose- and time-dependent manner in overweight/obese African Americans with suboptimal vitamin D status as defined by&#x000a0;serum 25(OH)D level&#x02009;&#x02264;&#x02009;20&#x000a0;ng/mL [<xref ref-type="bibr" rid="CR6">6</xref>]. By monthly dosing, 2000&#x000a0;IU and 4000&#x000a0;IU vitamin D, rather than 600&#x000a0;IU, are both efficient in optimizing vitamin D status over 16&#x000a0;weeks. Of note, the current RDA of 600&#x000a0;IU/day is not well studied in African Americans. Previous dose&#x02013;response trial in nursing home residents in Boston [<xref ref-type="bibr" rid="CR27">27</xref>] reported that 600&#x000a0;IU/day vitamin D may not be adequate in achieving a 25(OHD) level of 30&#x000a0;ng/mL. In the elderly living in the Netherlands with suboptimal vitamin D status, a dose of 600&#x000a0;IU/day did not achieve the level of 30&#x000a0;ng/mL either by daily, weekly or monthly dosing after ~4&#x000a0;months [<xref ref-type="bibr" rid="CR28">28</xref>].</p><p>One of the most interesting findings of our study was that the 25(OH)D concentrations at posttest between the 4000&#x000a0;IU and 2000&#x000a0;IU groups did not differ. The mean 25(OH)D concentrations in the 4000&#x000a0;IU group seemed to plateau and become similar to the 25(OH)D concentrations in the 2000&#x000a0;IU group. In the dose&#x02013;response trial by Gallagher in post-menopausal Caucasian females with 25(OH)D concentrations below 20&#x000a0;ng/mL, [<xref ref-type="bibr" rid="CR29">29</xref>] the 25(OH)D concentrations increased in a quadratic, rather than a linear pattern with an increasing vitamin D dose from 400&#x02013;4800&#x000a0;IU/day. The 25(OH)D concentrations in their study began to plateau at the dose of ~4000&#x000a0;IU. In a subset of African Americans [<xref ref-type="bibr" rid="CR12">12</xref>], the dose&#x02013;response curves for 25(OH)D concentrations were linear. The authors speculated that the observed racial differences could be due to a very small number of African Americans in the 3200 and 4000&#x000a0;IU groups. There are few dose&#x02013;response RCTs comparing 2000&#x000a0;IU and 4000&#x000a0;IU doses. Pregnant Arab females with vitamin D deficiency were previously supplemented with 400, 2000, or 4000&#x000a0;IU/day [<xref ref-type="bibr" rid="CR30">30</xref>]. The 25(OH)D responses in the 2000 and the 4000&#x000a0;IU groups paralleled from 12&#x02013;16 weeks of gestation (baseline) to 28&#x000a0;weeks of gestation (~16&#x000a0;weeks), as observed in our study. Heaney and colleagues [<xref ref-type="bibr" rid="CR31">31</xref>] suggest that at a lower concentration of 25(OH)D, the conversion of vitamin D<sub>3</sub> from oral or cutaneous intake into 25(OH)D follows first-order kinetics, which later switches to a slower, zero-order with saturation of hepatic 25-hydroxylase and the 25(OH)D levels start to plateau. The serum 25(OH)D concentration at which this change occurs was calculated to be ~35.2&#x000a0;ng/mL. In our study, the 4000&#x000a0;IU group by monthly dosing achieved mean serum 25(OH)D concentrations of 35.66&#x02009;&#x000b1;&#x02009;3.4&#x000a0;ng/mL as early as 8-weeks, making it plausible that the rate of conversion into 25(OH)D might have diminished from 8-week onwards. On the other hand, the 2000&#x000a0;IU achieved mean serum 25(OH)D concentrations of 30.50&#x02009;&#x000b1;&#x02009;2.1&#x000a0;ng/mL at 8-weeks and continued to increase to 16-weeks. Our data indicate that a dose of 2000&#x000a0;IU by monthly dosing may be appropriate to improve the vitamin D status up to the level of 30&#x000a0;ng/mL, but 4000&#x000a0;IU can achieve it more rapidly.</p></sec><sec id="Sec16"><title>1,25(OH)<sub>2</sub>D</title><p>We demonstrated dose- and time-dependent increases in 1,25(OH)<sub>2</sub>D concentrations, and 1,25(OH)<sub>2</sub>D concentrations can be raised by 2000 or 4000&#x000a0;IU in a monthly dosing as early as 8&#x000a0;weeks. Provided the continuous increase of 1,25(OH)<sub>2</sub>D concentrations at 16-weeks by 4000&#x000a0;IU in the present study, though marginally significant, future RCTs with a larger sample size are warranted. To the best of our knowledge, there was only one previous study evaluating the dose-responsiveness of 1,25(OH)<sub>2</sub>D to vitamin D supplementation, in which no significant dose-dependent increases in 1,25(OH)<sub>2</sub>D were observed in a population of African American and Caucasian children with daily doses ranging from 400 to 4000&#x000a0;IU of vitamin D supplements for 12&#x000a0;weeks [<xref ref-type="bibr" rid="CR32">32</xref>]. The disparities of the findings could be due to the differences in the baseline 25(OH)D levels or the frequency of dosing.</p></sec><sec id="Sec17"><title>iPTH</title><p>We observed dose- and time-responsive reductions in plasma iPTH concentrations, whereas mixed results in this regard have been reported in the literature [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. The present study demonstrated that 4000&#x000a0;IU, rather than 600 or 2000&#x000a0;IU by monthly dosing, significantly reduced iPTH at 8- and 16-weeks. Our group previously reported that iPTH concentrations in response to 2000&#x000a0;IU/day was unchanged in African American adolescents [<xref ref-type="bibr" rid="CR3">3</xref>] and adults [<xref ref-type="bibr" rid="CR26">26</xref>], which is in agreement with the findings of others [<xref ref-type="bibr" rid="CR33">33</xref>]. These findings may reinforce it that a dose higher than 2000&#x000a0;IU/day would be required to suppress iPTH. However, a higher daily vitamin D dose, i.e., ~5000&#x000a0;IU/day, modestly yet insignificantly reduced iPTH, as compared to 1000 and 2000&#x000a0;IU/day, respectively [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Thus, our results might indicate the superiority of monthly dosing in suppressing iPTH.</p></sec><sec id="Sec18"><title>FGF-23 and phosphorus</title><p>To the best of our knowledge, our study is among the few to report FGF-23 and phosphorus in apparently healthy African Americans, and the first to study the dose-responsiveness to vitamin D supplementation. Of note, baseline plasma intact FGF-23 levels in our African American subjects were lower than previously reported [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. We did not observe any dose- or time-dependent changes in either FGF-23 or phosphorus. Eighteen otherwise healthy premenopausal Turkish females with serum 25(OH)D concentrations below 30&#x000a0;ng/mL were previously given a loading dose of 150,000&#x000a0;IU vitamin D<sub>3</sub> followed by daily 880&#x000a0;IU plus 1000&#x000a0;mg calcium for 6&#x000a0;weeks [<xref ref-type="bibr" rid="CR25">25</xref>]. At posttest, significant reductions in FGF-23 and phosphorus were observed. Another study by Turner and colleagues in 45 osteoporotic older males and females with serum 25(OH)D concentrations below 20&#x000a0;ng/mL administered a single loading dose of 300,000&#x000a0;IU vitamin D<sub>2</sub> intramuscular followed by daily 800&#x000a0;IU of vitamin D<sub>3</sub> plus 1200&#x000a0;mg calcium orally for 3&#x000a0;months [<xref ref-type="bibr" rid="CR37">37</xref>]. Significant increases were observed in FGF-23 and phosphorus at 1, 2, and 3&#x000a0;months. By supplementing weekly 50,000&#x000a0;IU vitamin D<sub>2</sub> plus calcium in individuals between 18&#x02013;45 years of age with serum 25(OH)D levels below 20&#x000a0;ng/mL, Burnett-Bowie and colleagues reported a significant increase in FGF-23 with no changes in phosphate concentrations after 8- and 12-weeks [<xref ref-type="bibr" rid="CR38">38</xref>]. Thus, FGF-23 and phosphate changes in response to vitamin D supplementation are inconsistent. All these observed discrepancies could be due to, 1) the various dosing regimens; or 2) the differences in assay methods, e.g., intact FGF-23 versus c-terminal FGF-23; or 3) the use of calcium with vitamin D supplementation; or 4) low baseline FGF-23 levels in our study. We also speculate that in our study the changes of the two stimulants for FGF-23, i.e. the reductions in iPTH and increases in 1,25(OH)<sub>2</sub>D, might have kept the FGF-23 concentrations unchanged. Last, the control of circulating concentrations of FGF-23 is a complex matter, and monthly versus daily dosing may result in fluctuations in the concentrations of circulating FGF-23 [<xref ref-type="bibr" rid="CR39">39</xref>].</p></sec><sec id="Sec19"><title>Strengths and limitations</title><p>There are several strengths in the present study. We exclusively recruited overweight/obese African American participants with suboptimal vitamin D status. We comprehensively analyzed various vitamin D related biomarkers, and administered vitamin D supplements without calcium supplements. The doses selected in this study were based on the current RDA and UL by the IOM, [<xref ref-type="bibr" rid="CR6">6</xref>] and monthly supervised dosing scheme was undertaken to ensure 100&#x000a0;% compliance. Although monthly vitamin D dosing has been previously administered, our study is the first to use a dose&#x02013;response design. The limitations of our study are worth mentioning. First, the bioavailability of 25(OH)D was not included in the current study, although we only supplemented African Americans [<xref ref-type="bibr" rid="CR40">40</xref>]. Second, the participants were recruited in different seasons. However, only individuals with suboptimal vitamin D status were recruited irrespective of the season of enrollment, and the results did not alter after adjusting for seasons. Third, the female representation was higher in our sample compared to males. However, the gender distribution was not different among groups, and the results did not differ after adjusting for gender as a potential confounder. Fourth, the objective of the current study is to study a panel of circulating vitamin D biomarkers in response to vitamin D supplementation. Skeletal and extra-skeletal functional outcomes, that are not part of this study, would deserve investigations in the future, to help to select doses and time scheme. Finally, the sample size in each group was relatively small, which emphasizes the need for larger studies.</p></sec></sec><sec id="Sec20" sec-type="conclusions"><title>Conclusions</title><p>In summary, circulating 25(OH)D, 1,25(OH)<sub>2</sub>D, and iPTH concentrations, but not FGF-23, phosphorus and urine calcium, respond to monthly vitamin D supplementation in a time- and dose-dependent manner. Both 2000&#x000a0;IU and 4000&#x000a0;IU vitamin D in monthly dosing appear to be comparable and effective in achieving the 25(OH)D level of 30&#x000a0;ng/mL, but 4000&#x000a0;IU optimizes vitamin D status more rapidly. In monthly dosing, 4000&#x000a0;IU suppresses iPTH rapidly, and the suppression seems to sustain over time. The biological benefits of 4000&#x000a0;IU vitamin D needs to be further investigated in well-designed, larger RCTs with skeletal and extra-skeletal outcomes.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>25(OH)D</term><def><p>25-hydroxyvitamin D</p></def></def-item><def-item><term>IOM</term><def><p>Institute of Medicine</p></def></def-item><def-item><term>RCT</term><def><p>Randomized clinical trials</p></def></def-item><def-item><term>1,25(OH)<sub>2</sub>D</term><def><p>1,25-dihydroxyvitamin D</p></def></def-item><def-item><term>PTH</term><def><p>Parathyroid hormone</p></def></def-item><def-item><term>FGF-23</term><def><p>Fibroblast growth factor-23</p></def></def-item><def-item><term>RDA</term><def><p>Recommended dietary allowance</p></def></def-item><def-item><term>BMI</term><def><p>Body mass index</p></def></def-item><def-item><term>IRB</term><def><p>Institutional review board</p></def></def-item><def-item><term>DEQAS</term><def><p>Vitamin D external quality assessment scheme</p></def></def-item><def-item><term>iPTH</term><def><p>Intact parathyroid hormone</p></def></def-item><def-item><term>ELISA</term><def><p>Enzyme-linked immunosorbent assay</p></def></def-item><def-item><term>SD</term><def><p>Standard deviation</p></def></def-item><def-item><term>SEM</term><def><p>Standard error of mean</p></def></def-item><def-item><term>Ca/Cr</term><def><p>Calcium/creatinine ratio</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>YD, HZ and JB conceptualized and designed the study, drafted the initial manuscript, and critically reviewed and revised the manuscript, and approved the final manuscript as submitted. JB, YD, NP and SP carried out statistical analyses, interpreted data, critically reviewed and revised the manuscript, and approved the final manuscript as submitted. JB, SP, IK, RH, YH, CC, YTD, AR, MP, EA and SK did data collection, reviewed and revised the manuscript, and approved the final manuscript as submitted. YH and DG conducted bio-assays and reviewed and revised the manuscript, and approved the final manuscript as submitted.</p></fn></fn-group><ack><title>Acknowledgement</title><p>We thank our subjects for participating in our study and Biotech Pharmacal, Inc. to supply vitamin D and placebo capsules at no cost. We also thank Marjorie Phillips and Darla Irwin in the Clinical Research Pharmacy.</p><sec id="FPar1"><title>Funding</title><p>The Diabetes and Obesity Discovery Institute, Georgia Regents University as a part of research support to JB (American Board of Internal Medicine research residency track) and NHLBI-R01 HL077230 to YD.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Looker AC, Johnson CL, Lacher DA, Pfeiffer CM, Schleicher RL, Sempos CT. Vitamin D status: United States, 2001&#x02013;2006. NCHS data brief. 2011(59):1&#x02013;8. PubMed.</mixed-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forrest</surname><given-names>KY</given-names></name><name><surname>Stuhldreher</surname><given-names>WL</given-names></name></person-group><article-title>Prevalence and correlates of vitamin D deficiency in US adults</article-title><source>Nutr Res</source><year>2011</year><volume>31</volume><issue>1</issue><fpage>48</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/j.nutres.2010.12.001</pub-id><pub-id pub-id-type="pmid">21310306</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Stallmann-Jorgensen</surname><given-names>IS</given-names></name><name><surname>Pollock</surname><given-names>NK</given-names></name><name><surname>Harris</surname><given-names>RA</given-names></name><name><surname>Keeton</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A 16-week randomized clinical trial of 2000 international units daily vitamin D3 supplementation in black youth: 25-hydroxyvitamin D, adiposity, and arterial stiffness</article-title><source>J Clin Endocrinol Metab</source><year>2010</year><volume>95</volume><issue>10</issue><fpage>4584</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1210/jc.2010-0606</pub-id><pub-id pub-id-type="pmid">20660028</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. The American journal of clinical nutrition. 2000;72(3):690&#x02013;3. PubMed</mixed-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallagher</surname><given-names>JC</given-names></name><name><surname>Yalamanchili</surname><given-names>V</given-names></name><name><surname>Smith</surname><given-names>LM</given-names></name></person-group><article-title>The effect of vitamin D supplementation on serum 25(OH)D in thin and obese women</article-title><source>J Steroid Biochem Mol Biol</source><year>2013</year><volume>136</volume><fpage>195</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1016/j.jsbmb.2012.12.003</pub-id><pub-id pub-id-type="pmid">23246640</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>AC</given-names></name></person-group><article-title>The 2011 report on dietary reference intakes for calcium and vitamin D</article-title><source>Public Health Nutr</source><year>2011</year><volume>14</volume><issue>5</issue><fpage>938</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1017/S1368980011000565</pub-id><pub-id pub-id-type="pmid">21492489</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawson-Hughes</surname><given-names>B</given-names></name><name><surname>Heaney</surname><given-names>RP</given-names></name><name><surname>Holick</surname><given-names>MF</given-names></name><name><surname>Lips</surname><given-names>P</given-names></name><name><surname>Meunier</surname><given-names>PJ</given-names></name><name><surname>Vieth</surname><given-names>R</given-names></name></person-group><article-title>Estimates of optimal vitamin D status</article-title><source>Osteoporos Int</source><year>2005</year><volume>16</volume><issue>7</issue><fpage>713</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1007/s00198-005-1867-7</pub-id><pub-id pub-id-type="pmid">15776217</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawson-Hughes</surname><given-names>B</given-names></name><name><surname>Mithal</surname><given-names>A</given-names></name><name><surname>Bonjour</surname><given-names>JP</given-names></name><name><surname>Boonen</surname><given-names>S</given-names></name><name><surname>Burckhardt</surname><given-names>P</given-names></name><name><surname>Fuleihan</surname><given-names>GE</given-names></name><etal/></person-group><article-title>IOF position statement: vitamin D recommendations for older adults</article-title><source>Osteoporos Int</source><year>2010</year><volume>21</volume><issue>7</issue><fpage>1151</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1007/s00198-010-1285-3</pub-id><pub-id pub-id-type="pmid">20422154</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Souberbielle</surname><given-names>JC</given-names></name><name><surname>Body</surname><given-names>JJ</given-names></name><name><surname>Lappe</surname><given-names>JM</given-names></name><name><surname>Plebani</surname><given-names>M</given-names></name><name><surname>Shoenfeld</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>TJ</given-names></name><etal/></person-group><article-title>Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice</article-title><source>Autoimmun Rev</source><year>2010</year><volume>9</volume><issue>11</issue><fpage>709</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.autrev.2010.06.009</pub-id><pub-id pub-id-type="pmid">20601202</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holick</surname><given-names>MF</given-names></name><name><surname>Binkley</surname><given-names>NC</given-names></name><name><surname>Bischoff-Ferrari</surname><given-names>HA</given-names></name><name><surname>Gordon</surname><given-names>CM</given-names></name><name><surname>Hanley</surname><given-names>DA</given-names></name><name><surname>Heaney</surname><given-names>RP</given-names></name><etal/></person-group><article-title>Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline</article-title><source>J Clin Endocrinol Metab</source><year>2011</year><volume>96</volume><issue>7</issue><fpage>1911</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1210/jc.2011-0385</pub-id><pub-id pub-id-type="pmid">21646368</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talwar</surname><given-names>SA</given-names></name><name><surname>Aloia</surname><given-names>JF</given-names></name><name><surname>Pollack</surname><given-names>S</given-names></name><name><surname>Yeh</surname><given-names>JK</given-names></name></person-group><article-title>Dose response to vitamin D supplementation among postmenopausal African American women</article-title><source>Am J Clin Nutr</source><year>2007</year><volume>86</volume><issue>6</issue><fpage>1657</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">18065583</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallagher</surname><given-names>JC</given-names></name><name><surname>Jindal</surname><given-names>P</given-names></name><name><surname>Lynette</surname><given-names>MS</given-names></name></person-group><article-title>Vitamin D does not Increase Calcium Absorption in Young Women: A Randomized Clinical Trial</article-title><source>J Bone Miner Res</source><year>2013</year></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>K</given-names></name><name><surname>Scott</surname><given-names>JB</given-names></name><name><surname>Drake</surname><given-names>BF</given-names></name><name><surname>Chan</surname><given-names>AT</given-names></name><name><surname>Hollis</surname><given-names>BW</given-names></name><name><surname>Chandler</surname><given-names>PD</given-names></name><etal/></person-group><article-title>Dose response to vitamin D supplementation in African Americans: results of a 4-arm, randomized, placebo-controlled trial</article-title><source>Am J Clin Nutr</source><year>2013</year></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sai</surname><given-names>AJ</given-names></name><name><surname>Walters</surname><given-names>RW</given-names></name><name><surname>Fang</surname><given-names>X</given-names></name><name><surname>Gallagher</surname><given-names>JC</given-names></name></person-group><article-title>Relationship between vitamin D, parathyroid hormone, and bone health</article-title><source>J Clin Endocrinol Metab</source><year>2011</year><volume>96</volume><issue>3</issue><fpage>E436</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1210/jc.2010-1886</pub-id><pub-id pub-id-type="pmid">21159838</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginde</surname><given-names>AA</given-names></name><name><surname>Wolfe</surname><given-names>P</given-names></name><name><surname>Camargo</surname><given-names>CA</given-names><suffix>Jr</suffix></name><name><surname>Schwartz</surname><given-names>RS</given-names></name></person-group><article-title>Defining vitamin D status by secondary hyperparathyroidism in the U.S. population</article-title><source>J Endocrinol Invest</source><year>2012</year><volume>35</volume><issue>1</issue><fpage>42</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">21606669</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname><given-names>H</given-names></name><name><surname>Kusano</surname><given-names>K</given-names></name><name><surname>Kinosaki</surname><given-names>M</given-names></name><name><surname>Ito</surname><given-names>H</given-names></name><name><surname>Hirata</surname><given-names>M</given-names></name><name><surname>Segawa</surname><given-names>H</given-names></name><etal/></person-group><article-title>Human fibroblast growth factor-23 mutants suppress Na&#x02009;+&#x02009;&#x02212;dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><issue>4</issue><fpage>2206</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1074/jbc.M207872200</pub-id><pub-id pub-id-type="pmid">12419819</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimada</surname><given-names>T</given-names></name><name><surname>Kakitani</surname><given-names>M</given-names></name><name><surname>Yamazaki</surname><given-names>Y</given-names></name><name><surname>Hasegawa</surname><given-names>H</given-names></name><name><surname>Takeuchi</surname><given-names>Y</given-names></name><name><surname>Fujita</surname><given-names>T</given-names></name><etal/></person-group><article-title>Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism</article-title><source>J Clin Invest</source><year>2004</year><volume>113</volume><issue>4</issue><fpage>561</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1172/JCI200419081</pub-id><pub-id pub-id-type="pmid">14966565</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramon</surname><given-names>I</given-names></name><name><surname>Kleynen</surname><given-names>P</given-names></name><name><surname>Body</surname><given-names>JJ</given-names></name><name><surname>Karmali</surname><given-names>R</given-names></name></person-group><article-title>Fibroblast growth factor 23 and its role in phosphate homeostasis</article-title><source>Eur J Endocrinol</source><year>2010</year><volume>162</volume><issue>1</issue><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1530/EJE-09-0597</pub-id><pub-id pub-id-type="pmid">19776202</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname><given-names>H</given-names></name><name><surname>Maeda</surname><given-names>A</given-names></name><name><surname>Ohtomo</surname><given-names>S</given-names></name><name><surname>Hirata</surname><given-names>M</given-names></name><name><surname>Kusano</surname><given-names>K</given-names></name><name><surname>Kato</surname><given-names>S</given-names></name><etal/></person-group><article-title>Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><issue>4</issue><fpage>2543</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1074/jbc.M408903200</pub-id><pub-id pub-id-type="pmid">15531762</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Washington (DC)1997.</mixed-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murdoch</surname><given-names>DR</given-names></name><name><surname>Slow</surname><given-names>S</given-names></name><name><surname>Chambers</surname><given-names>ST</given-names></name><name><surname>Jennings</surname><given-names>LC</given-names></name><name><surname>Stewart</surname><given-names>AW</given-names></name><name><surname>Priest</surname><given-names>PC</given-names></name><etal/></person-group><article-title>Effect of vitamin D3 supplementation on upper respiratory tract infections in healthy adults: the VIDARIS randomized controlled trial</article-title><source>JAMA</source><year>2012</year><volume>308</volume><issue>13</issue><fpage>1333</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1001/jama.2012.12505</pub-id><pub-id pub-id-type="pmid">23032549</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoenmakers</surname><given-names>I</given-names></name><name><surname>Francis</surname><given-names>RM</given-names></name><name><surname>McColl</surname><given-names>E</given-names></name><name><surname>Chadwick</surname><given-names>T</given-names></name><name><surname>Goldberg</surname><given-names>GR</given-names></name><name><surname>Harle</surname><given-names>C</given-names></name><etal/></person-group><article-title>Vitamin D supplementation in older people (VDOP): Study protocol for a randomised controlled intervention trial with monthly oral dosing with 12,000&#x000a0;IU, 24,000&#x000a0;IU or 48,000&#x000a0;IU of vitamin D(3)</article-title><source>Trials</source><year>2013</year><volume>14</volume><fpage>299</fpage><pub-id pub-id-type="doi">10.1186/1745-6215-14-299</pub-id><pub-id pub-id-type="pmid">24041337</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Saadi HF, Dawodu A, Afandi BO, Zayed R, Benedict S, Nagelkerke N. Efficacy of daily and monthly high-dose calciferol in vitamin D-deficient nulliparous and lactating women. The American journal of clinical nutrition. 2007;85(6):1565&#x02013;71. PubMed.</mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Hollis BW, Kamerud JQ, Kurkowski A, Beaulieu J, Napoli JL. Quantification of circulating 1,25-dihydroxyvitamin D by radioimmunoassay with 125I-labeled tracer. Clinical chemistry. 1996;42(4):586&#x02013;92. PubMed.</mixed-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uzum</surname><given-names>AK</given-names></name><name><surname>Salman</surname><given-names>S</given-names></name><name><surname>Telci</surname><given-names>A</given-names></name><name><surname>Boztepe</surname><given-names>H</given-names></name><name><surname>Tanakol</surname><given-names>R</given-names></name><name><surname>Alagol</surname><given-names>F</given-names></name><etal/></person-group><article-title>Effects of vitamin D replacement therapy on serum FGF23 concentrations in vitamin D-deficient women in short term</article-title><source>Eur J Endocrinol</source><year>2010</year><volume>163</volume><issue>5</issue><fpage>825</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1530/EJE-10-0591</pub-id><pub-id pub-id-type="pmid">20732956</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>RA</given-names></name><name><surname>Pedersen-White</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>DH</given-names></name><name><surname>Stallmann-Jorgensen</surname><given-names>IS</given-names></name><name><surname>Keeton</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Vitamin D3 supplementation for 16&#x000a0;weeks improves flow-mediated dilation in overweight African-American adults</article-title><source>Am J Hypertens</source><year>2011</year><volume>24</volume><issue>5</issue><fpage>557</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1038/ajh.2011.12</pub-id><pub-id pub-id-type="pmid">21311504</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broe</surname><given-names>KE</given-names></name><name><surname>Chen</surname><given-names>TC</given-names></name><name><surname>Weinberg</surname><given-names>J</given-names></name><name><surname>Bischoff-Ferrari</surname><given-names>HA</given-names></name><name><surname>Holick</surname><given-names>MF</given-names></name><name><surname>Kiel</surname><given-names>DP</given-names></name></person-group><article-title>A higher dose of vitamin d reduces the risk of falls in nursing home residents: a randomized, multiple-dose study</article-title><source>J Am Geriatr Soc</source><year>2007</year><volume>55</volume><issue>2</issue><fpage>234</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/j.1532-5415.2007.01048.x</pub-id><pub-id pub-id-type="pmid">17302660</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chel</surname><given-names>V</given-names></name><name><surname>Wijnhoven</surname><given-names>HA</given-names></name><name><surname>Smit</surname><given-names>JH</given-names></name><name><surname>Ooms</surname><given-names>M</given-names></name><name><surname>Lips</surname><given-names>P</given-names></name></person-group><article-title>Efficacy of different doses and time intervals of oral vitamin D supplementation with or without calcium in elderly nursing home residents</article-title><source>Osteoporos Int</source><year>2008</year><volume>19</volume><issue>5</issue><fpage>663</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1007/s00198-007-0465-2</pub-id><pub-id pub-id-type="pmid">17874029</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallagher</surname><given-names>JC</given-names></name><name><surname>Sai</surname><given-names>A</given-names></name><name><surname>Templin</surname><given-names>T</given-names><suffix>2nd</suffix></name><name><surname>Smith</surname><given-names>L</given-names></name></person-group><article-title>Dose response to vitamin D supplementation in postmenopausal women: a randomized trial</article-title><source>Ann Intern Med</source><year>2012</year><volume>156</volume><issue>6</issue><fpage>425</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-156-6-201203200-00005</pub-id><pub-id pub-id-type="pmid">22431675</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawodu</surname><given-names>A</given-names></name><name><surname>Saadi</surname><given-names>HF</given-names></name><name><surname>Bekdache</surname><given-names>G</given-names></name><name><surname>Javed</surname><given-names>Y</given-names></name><name><surname>Altaye</surname><given-names>M</given-names></name><name><surname>Hollis</surname><given-names>BW</given-names></name></person-group><article-title>Randomized controlled trial (RCT) of vitamin D supplementation in pregnancy in a population with endemic vitamin D deficiency</article-title><source>J Clin Endocrinol Metab</source><year>2013</year><volume>98</volume><issue>6</issue><fpage>2337</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1210/jc.2013-1154</pub-id><pub-id pub-id-type="pmid">23559082</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">Heaney RP, Armas LA, Shary JR, Bell NH, Binkley N, Hollis BW. 25-Hydroxylation of vitamin D3: relation to circulating vitamin D3 under various input conditions. The American journal of clinical nutrition. 2008;87(6):1738&#x02013;42. PubMed.</mixed-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>RD</given-names></name><name><surname>Laing</surname><given-names>EM</given-names></name><name><surname>Hill Gallant</surname><given-names>KM</given-names></name><name><surname>Hall</surname><given-names>DB</given-names></name><name><surname>McCabe</surname><given-names>GP</given-names></name><name><surname>Hausman</surname><given-names>DB</given-names></name><etal/></person-group><article-title>A randomized trial of vitamin d3 supplementation in children: dose&#x02013;response effects on vitamin d metabolites and calcium absorption</article-title><source>J Clin Endocrinol Metab</source><year>2013</year><volume>98</volume><issue>12</issue><fpage>4816</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1210/jc.2013-2728</pub-id><pub-id pub-id-type="pmid">24092833</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diamond</surname><given-names>T</given-names></name><name><surname>Wong</surname><given-names>YK</given-names></name><name><surname>Golombick</surname><given-names>T</given-names></name></person-group><article-title>Effect of oral cholecalciferol 2,000 versus 5,000&#x000a0;IU on serum vitamin D, PTH, bone and muscle strength in patients with vitamin D deficiency</article-title><source>Osteoporos Int</source><year>2013</year><volume>24</volume><issue>3</issue><fpage>1101</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1007/s00198-012-1944-7</pub-id><pub-id pub-id-type="pmid">22422304</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drincic</surname><given-names>A</given-names></name><name><surname>Fuller</surname><given-names>E</given-names></name><name><surname>Heaney</surname><given-names>RP</given-names></name><name><surname>Armas</surname><given-names>LA</given-names></name></person-group><article-title>25-hydroxyvitamin d response to graded vitamin d3 supplementation among obese adults</article-title><source>J Clin Endocrinol Metab</source><year>2013</year><volume>98</volume><issue>12</issue><fpage>4845</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1210/jc.2012-4103</pub-id><pub-id pub-id-type="pmid">24037880</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">Gutierrez OM, Smith KT, Barchi-Chung A, Patel NM, Isakova T, Wolf M. (1&#x02013;34) Parathyroid hormone infusion acutely lowers fibroblast growth factor 23 concentrations in adult volunteers. Clinical journal of the American Society of Nephrology : CJASN. 2012;7(1):139&#x02013;45. doi:10.2215/CJN.06240611. PubMed PMID: 22246283; PubMed Central PMCID: PMC3265347.</mixed-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gutierrez</surname><given-names>OM</given-names></name><name><surname>Isakova</surname><given-names>T</given-names></name><name><surname>Smith</surname><given-names>K</given-names></name><name><surname>Epstein</surname><given-names>M</given-names></name><name><surname>Patel</surname><given-names>N</given-names></name><name><surname>Wolf</surname><given-names>M</given-names></name></person-group><article-title>Racial differences in postprandial mineral ion handling in health and in chronic kidney disease</article-title><source>Nephrol Dial Transplant</source><year>2010</year><volume>25</volume><issue>12</issue><fpage>3970</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfq316</pub-id><pub-id pub-id-type="pmid">20530498</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>C</given-names></name><name><surname>Dalton</surname><given-names>N</given-names></name><name><surname>Inaoui</surname><given-names>R</given-names></name><name><surname>Fogelman</surname><given-names>I</given-names></name><name><surname>Fraser</surname><given-names>WD</given-names></name><name><surname>Hampson</surname><given-names>G</given-names></name></person-group><article-title>Effect of a 300 000-IU loading dose of ergocalciferol (Vitamin D2) on circulating 1,25(OH)2-vitamin D and fibroblast growth factor-23 (FGF-23) in vitamin D insufficiency</article-title><source>J Clin Endocrinol Metab</source><year>2013</year><volume>98</volume><issue>2</issue><fpage>550</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1210/jc.2012-2790</pub-id><pub-id pub-id-type="pmid">23284004</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnett-Bowie</surname><given-names>SA</given-names></name><name><surname>Leder</surname><given-names>BZ</given-names></name><name><surname>Henao</surname><given-names>MP</given-names></name><name><surname>Baldwin</surname><given-names>CM</given-names></name><name><surname>Hayden</surname><given-names>DL</given-names></name><name><surname>Finkelstein</surname><given-names>JS</given-names></name></person-group><article-title>Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23</article-title><source>Clin J Am Soc Nephrol</source><year>2012</year><volume>7</volume><issue>4</issue><fpage>624</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.2215/CJN.10030911</pub-id><pub-id pub-id-type="pmid">22300739</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollis</surname><given-names>BW</given-names></name><name><surname>Wagner</surname><given-names>CL</given-names></name></person-group><article-title>Clinical review: The role of the parent compound vitamin D with respect to metabolism and function: Why clinical dose intervals can affect clinical outcomes</article-title><source>J Clin Endocrinol Metab</source><year>2013</year><volume>98</volume><issue>12</issue><fpage>4619</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1210/jc.2013-2653</pub-id><pub-id pub-id-type="pmid">24106283</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powe</surname><given-names>CE</given-names></name><name><surname>Evans</surname><given-names>MK</given-names></name><name><surname>Wenger</surname><given-names>J</given-names></name><name><surname>Zonderman</surname><given-names>AB</given-names></name><name><surname>Berg</surname><given-names>AH</given-names></name><name><surname>Nalls</surname><given-names>M</given-names></name><etal/></person-group><article-title>Vitamin D-binding protein and vitamin D status of black Americans and white Americans</article-title><source>N Engl J Med</source><year>2013</year><volume>369</volume><issue>21</issue><fpage>1991</fpage><lpage>2000</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1306357</pub-id><pub-id pub-id-type="pmid">24256378</pub-id></element-citation></ref></ref-list></back></article>